A PYMNTS Company

US: Abbott sell products to Japan’s Terumo for $1.12 billion

By  |  October 19, 2016

Abbott Laboratories and St. Jude Medical Inc. will divest some of their cardiovascular products to Terumo Corp. for $1.12 billion in order to complete the $25 billion deal between the two medical device giants.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The all-cash transaction is conditioned on Abbott’s successful acquisition of St. Jude and antitrust regulatory approval, the companies said Tuesday in a statement. The sale includes St. Jude’s Angio-Seal and Femoseal vascular-closure products, and Abbott’s Vado Steerable Sheath, the companies said.

    Terumo, a medical equipment maker based in Japan, markets and sells products in the US, Europe and Asia. Abbott and St. Jude announced their merger valued at $25 billion in April and have said it’s expected to close by the end of the year. The sale was made to “satisfy regulatory review,” according to Candace Steele Flippin, a spokeswoman for St. Jude.

    Abbott will retain its vascular-closure products, and doesn’t expect the sale to have a major impact on its earnings, according to the statement.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletterr for more headlines and updates on antitrust developments around the world.